Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takahashi, H. K. Articles by Nishibori, M. Search for Related Content PubMed PubMed Citation Articles by Takahashi, H. K. Articles by Nishibori, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2005, p. 3228-3233, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3228-3233.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Effect of Ciprofloxacin-Induced Prostaglandin E₂ on Interleukin-18-Treated Monocytes

Hideo Kohka Takahashi,^1,2,3 Hiromi Iwagaki,² Dong Xue,² Goutarou Katsuno,² Sachi Sugita,¹ Kenji Mizuno,² Shuji Mori,¹ Shinya Saito,² Tadashi Yoshino,³ Noriaki Tanaka,² and Masahiro Nishibori^1*

Department of Pharmacology,¹ Department of Gastroenterological Surgery, Transplant, and Surgical Oncology,² Department of Pathology, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama, Japan³

Received 22 November 2004/ Returned for modification 21 December 2004/ Accepted 5 February 2005

Top Abstract Introduction Materials and Methods Results Discussion References

 
Ciprofloxacin, a fluorinated 4-quinolone, is useful for the clinical treatment of infections due to its antibacterial properties and also modulates the immune response of monocytes isolated from human peripheral blood mononuclear cells. In the present study, we found that ciprofloxacin induced the production of prostaglandin E₂ in monocytes in a concentration-dependent manner regardless of the presence of interleukin-18 by enhancing the expression of cyclooxygenase-2 protein and that this in turn led to the elevation of intercellular cyclic AMP in monocytes via the stimulation of prostaglandin receptors. The prostaglandin E₂ and cyclic AMP production increased by ciprofloxacin was inhibited by indomethacin, a nonselective cyclooxygenase-2 inhibitor, and NS398, a selective cyclooxygenase-2 inhibitor. In addition, ciprofloxacin suppressed the interleukin-18-induced production of tumor necrosis factor alpha, gamma interferon, and interleukin-12 in peripheral blood mononuclear cells by inhibiting the expression of intercellular adhesion molecule 1, B7.1, B7.2, and CD40 on monocytes, and this effect could be reversed by the addition of indomethacin or NS398. These results indicate that ciprofloxacin exerts immunomodulatory activity via the production of prostaglandin E₂ and imply therapeutic potential of ciprofloxacin for the treatment of systemic inflammatory responses initiated by interleukin-18.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Interleukin-18 (IL-18) requires cleavage at its aspartic acid residue by IL-1ß-converting enzyme/caspase-1 to become an active and mature protein (8), and monocytes produce IL-18 while interacting with cognate T cells (10). Furthermore, IL-18 is located upstream of production of Th1 cytokines (8, 12), acts in synergy with IL-12 to induce gamma interferon (IFN-) production in CD4⁺ cells via different signaling pathways (2), and along with IL-12 is necessary for Th1 responses. Cell-to-cell interactions brought about via the engagement between intercellular adhesion molecule 1 (ICAM-1), B7.1, B7.2, CD40, and CD40L on monocytes and their ligands on T/NK cells are also involved in the IL-18-induced production of cytokines, including IL-12, tumor necrosis factor alpha (TNF-), IFN-, and IL-10 (20, 21).

A major product of cyclooxygenase (COX)-initiated arachidonic acid metabolism, prostaglandin E₂ (PGE₂), which is released from antigen-presenting cells, primes naive human T cells and enhances their production of anti-inflammatory cytokines while inhibiting their synthesis of proinflammatory cytokines (6, 9). Among the four PGE₂ receptor subtypes, E-prostanoid 1 (EP₁), EP₂, EP₃, and EP₄, activation of the EP₂ and EP₄ receptors leads to an increase in cyclic AMP (cAMP) levels and protein kinase A (PKA) activity (3). The stimulation of EP₂ receptors directly inhibits T-cell proliferation, while that of EP₂ and EP₄ receptors regulates antigen-presenting cell functions (11). In a previous study, we found that PGE₂ prevented the IL-18-induced expression of ICAM-1, B7.2, and CD40 on monocytes and the production of IL-12, TNF-, and IFN- in human peripheral blood mononuclear cells (PBMC) (20, 21).

The effects of fluoroquinolone antibacterial agents on immune modulation have been well documented (16), and fluoroquinolones are known to exert their bactericidal activity by inhibiting bacterial type II topoisomerases (TOPO II), a major component of mitotic chromosomes. Ciprofloxacin (CIP), a fluorinated 4-quinolone, may interact with TOPO II in human T cells, because the quinolone derivative CP-115,953, which displays high specificity against mammalian TOPO II, mimics the inducing effect of CIP on the production of IL-2 (5, 17). The synthesis of IL-1ß and TNF- by lipopolysaccharide-stimulated human monocytes is significantly inhibited by CIP (18). However, little is known about the mechanism responsible for CIP activity, including the regulation of adhesion molecule expression.

In the present study, we found that CIP induces the production of PGE₂ in monocytes through the induction of COX-2 protein. Therefore, we analyzed the effect of CIP-induced PGE₂ production on the expression of ICAM-1, B7.1, B7.2, CD40, and CD40L on monocytes and the production of IL-12, TNF-, IFN-, and IL-10 in PBMC using COX inhibitors in the presence and absence of IL-18.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Reagents and drugs. Recombinant human IL-18 was purchased from MBL (Nagoya, Japan), and CIP [1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid] was kindly provided by Bayer Yakuhin, Ltd (Osaka, Japan). NS398 and indomethacin were purchased from Cayman Chemical (Ann Arbor, MI), and H-89 was purchased from Sigma Chemical (St. Louis, MO). For flow cytometric analysis, fluorescein isothiocyanate (FITC)-conjugated mouse immunoglobulin G1 (IgG1) monoclonal antibody (MAb) against ICAM-1 and phycoerythrin-conjugated anti-CD14 MAb were acquired from DAKO (Glostrup, Denmark). FITC-conjugated anti-B7.1 MAb (mouse IgG1) was purchased from IMMUNOTECH (Marseille, France), and FITC-conjugated anti-B7.2 and anti-CD40 MAbs (mouse IgG1) were obtained from Pharmingen (San Diego, CA). Finally, FITC-conjugated IgG1 class-matched control was purchased from Sigma Chemical.

Isolation of PBMC and monocytes. Normal human PBMC were collected from human volunteers after obtaining their oral informed consent. Samples of 20 to 50 ml of peripheral blood were withdrawn from a forearm vein, after which the PBMC were isolated, and monocytes isolated from PBMC were separated by counterflow centrifugal elutriation as previously described (20, 21). The PBMC and monocytes were then suspended at a final concentration of 10⁶ cells/ml in the medium as previously described (20, 21).

Flow cytometric analysis. Monocytes at 10⁶ cells/ml were incubated with IL-18, CIP, NS398, indomethacin, and H-89 for 24 h at 37°C in a 5% CO₂-air mixture under different conditions, for which the reagents were added to the medium at the start of incubation. The cells at 5 x 10⁵ cells/sample were prepared as previously described (20, 21) and analyzed using a FACSCalibur (Becton Dickinson Biosciences, San Jose, CA), after which the data were processed using the CELL QUEST program (BD Biosciences). The results were presented as means ± standard errors of the mean (SEM) for five donors.

ELISAs. PBMC at 10⁶ cells/ml used to analyze cytokine production and monocytes at 10⁶ cells/ml used to analyze PGE₂ production were incubated for 24 h at 37°C in a 5% CO₂-air mixture under different conditions, for which the reagents were added to the medium at the start of incubation. After culture, IL-12 (p70), TNF-, IFN-, IL-10, and PGE₂ proteins in the cell suspensions were prepared as previously described (20, 21) and measured using an enzyme-linked immunosorbent assay (ELISA) kit (IL-12 [p70], TNF-, IFN-, and IL-10 were from R&D Systems, Minneapolis, MN, and PGE₂ was from Cayman Chemical), where the detection limits of the kit for IL-12 (p70), TNF-, IFN-, IL-10, and PGE₂ were 10 pg/ml. The results were expressed as means ± SEM for five donors.

Measurement of cAMP production in monocytes. Monocytes at 10⁶ cells/ml were incubated at 37°C in a 5% CO₂-air mixture under different conditions. After 24 h, cells at 2 x 10⁵ cells/200 µl/well were supplemented with trichloroacetic acid to a final concentration of 5% and 3-isobutyl-1-methylxanthine, an inhibitor of phosphodiesterase, at 100 µM and frozen at –80°C. Frozen samples were subsequently sonicated and assayed for cAMP using a cAMP enzyme immunoassay kit (Cayman Chemical) according to the manufacturer's instructions, for which no acetylation procedures were performed. The results were expressed as means ± SEM for five donors.

Western immunoblotting. For Western immunoblotting, monocytes at 10⁶ cells/ml were incubated with and without IL-18 or CIP for between 0 and 24 h at 37°C in a 5% CO₂-air mixture. After incubation, the cells were washed twice in phosphate-buffered saline before the addition of 60 ml of ice-cold lysis buffer (HEPES-buffered Hanks' balanced salt solution, pH 7.4, 0.5% Triton X-100, 10 mg/ml leupeptin, 10 mg/ml aprotinin) and 60 µl of 2x sample buffer (0.125 M Trizma base, pH 6.8, 20% glycerol, 4% sodium dodecyl sulfate, 10% 2-mercaptoethanol). The samples were then heated at 95°C for 7 min before being stored at –20°C. Sample proteins (50 ml/lane) were separated on 9% acrylamide gel and transferred onto Trans-Blot membranes at 4°C for 16 h at 300 mA, after which the membranes were blocked for 1 h at 25°C in Tris-buffered saline (25 mM Tris-HCl, 0.2 M NaCl, 0.15% Tween 20, pH 7.6) containing 5% dried milk (wt/vol). Next, the membranes were treated with horseradish peroxidase-conjugated rabbit polyclonal Ab against human COX-1 and COX-2 (Cayman Chemical) and ß-actin (Sigma Chemical).

Statistical analysis. Statistical significance was evaluated using analysis of variance followed by Dunnet's test, where a probability value less than 0.05 was considered to indicate significance.

Top Abstract Introduction Materials and Methods Results Discussion References

 
The effect of CIP on COX-1 and COX-2 protein expression in monocytes. The effect of 100 µg/ml CIP on COX-1 and COX-2 protein expression in monocytes in the presence and absence of 100 ng/ml IL-18 was determined by Western blot analysis after 24 h of incubation (Fig. 1). COX-1 and COX-2 expression in monocytes cultured in the medium was marginal, but the addition of CIP in the presence and absence of IL-18 remarkably induced the expression of COX-2 24 h after the start of the incubation.

View larger version (39K): [in this window] [in a new window]

FIG. 1. The effect of CIP on the expression of COX-1 and COX-2 protein in monocytes. The expression of COX-1 and COX-2 protein in monocytes at 106 cells/ml induced by 100 µg/ml CIP in the presence or absence of 100 ng/ml IL-18 after 24 h of incubation was determined by Western immunoblotting as described in Materials and Methods. ß-Actin was used as a control to correct for loading.

The effect of CIP on PGE₂ production in monocytes. The effect of 0 to 100 µg/ml CIP on PGE₂ production in medium from incubated monocytes in the presence and absence of 100 ng/ml IL-18 was determined by ELISA after 24 h of incubation (Fig. 2A). IL-18 had no effect on the production of PGE₂, but production induced by 100 µg/ml CIP increased in a time-dependent manner and reached a maximum level after 24 h. The CIP concentration directly elicited the production of PGE₂ in both the presence and absence of IL-18. At 100 µg/ml, CIP induced 30 nM PGE₂ production irrespective of the presence of IL-18. The 50% effective doses for the effect of CIP on the production of PGE₂ in the presence and absence of IL-18 were 2 and 20 µg/ml, respectively.

View larger version (30K): [in this window] [in a new window]

FIG. 2. The effect of CIP on the production of PGE2 in monocytes. (A) Monocytes at 106 cells/ml were incubated with between 0 and 100 µg/ml CIP in the presence and absence of 100 ng/ml IL-18 for 24 h. After treatment, the production of PGE2 was determined by ELISA. **, P < 0.01 compared with the value for medium alone; ##, P < 0.01 compared with the value for IL-18. (B) Monocytes at 106 cells/ml were incubated with between 0 and 10–4 M indomethacin, NS398, and H-89 in the presence and absence of 100 ng/ml IL-18 or 100 µg/ml CIP for 24 h. After the treatment, the production of PGE2 was determined by ELISA. **, P < 0.01 compared with the value for CIP; ##, P < 0.01 compared with the value for IL-18 and CIP. Filled circles and filled squares represent the results obtained with medium and IL-18, respectively. The results are the means ± SEM for five donors. When an error bar was within a symbol, the bar was omitted.

The effect of indomethacin and NS398 on the CIP-induced production of PGE₂ in monocytes. The effects of different concentrations ranging between 10^–7 and 10^–4 M indomethacin, a nonselective COX-2 inhibitor, and NS398, a selective COX-2 inhibitor, on the CIP-enhanced production of PGE₂ in monocytes in the presence and absence of 100 ng/ml IL-18 were determined by ELISA after 24 h of incubation (Fig. 2B). NS398 and indomethacin inhibited the production of PGE₂ irrespective of the presence of IL-18 in a concentration-dependent manner.

The effect of CIP on cAMP production in monocytes. The effect of 100 µg/ml CIP and 30 nM PGE₂ on the elevation of intercellular cAMP in monocytes in the presence and absence of 100 ng/ml IL-18 was determined by ELISA (Fig. 3). IL-18 had no effect on the production of cAMP, but CIP and PGE₂ elicited production irrespective of the presence of IL-18. Also, NS398 at 10^–4 M blocked the inhibitory effect of CIP on the production of cAMP irrespective of the presence of IL-18.

View larger version (21K): [in this window] [in a new window]

FIG. 3. The effect of CIP on the production of cAMP in monocytes. Monocytes at 106 cells/ml were incubated with 0.1 mM NS398, 100 ng/ml IL-18, 100 µg/ml CIP, or 30 nM PGE2 for 24 h. After treatment, the production of cAMP was determined by ELISA. **, P < 0.01 compared with the value for medium; ##, P < 0.01 compared with the value for IL-18. The results are the means ± SEM for five donors. When an error bar was within a symbol, the bar was omitted. ND, not detected.

The effect of CIP on the expression of ICAM-1, B7.1, B7.2, CD40, and CD40L on monocytes. The effects of 0 to 100 µg/ml CIP on the changes in expression of ICAM-1, B7.1, B7.2, CD40, and CD40L on monocytes in the presence and absence of 100 ng/ml IL-18 were determined by flow cytometry after 24 h. In the absence of IL-18, CIP inhibited the expression of ICAM-1, B7.1, B7.2, and CD40 (Fig. 4A) but had no effect on the expression of CD40L (data not shown). The expression of CD40 (data not shown) in addition to ICAM-1 and B7.2 (9) was up-regulated in a time-dependent manner by IL-18 at 100 ng/ml and reached a maximum after 24 h. IL-18 between 0 and 100 ng/ml elicited ICAM-1, B7.2, and CD40 expression in a concentration-dependent manner (20, 21), but the expression of B7.1 was not changed in the presence and absence of IL-18. CIP inhibited ICAM-1, B7.1, B7.2, and CD40 expression in a concentration-dependent manner in the presence of IL-18 (Fig. 4A) but had no effect on the expression of CD40L (data not shown). The 50% inhibitory concentrations for the inhibitory effect of CIP on the expression of ICAM-1, B7.1, B7.2, and CD40 in the presence of IL-18 were estimated as 2, 3, 2, and 2 µg/ml, respectively.

View larger version (33K): [in this window] [in a new window]

FIG. 4. The effect of CIP on the expression of ICAM-1, B7.1, B7.2, and CD40 on monocytes. (A) Monocytes at 106 cells/ml were incubated with between 0 and 100 µg/ml CIP in the presence and absence of 100 ng/ml IL-18 for 24 h. After treatment, the expression of ICAM-1, B7.1, B7.2, and CD40 was determined by flow cytometry. Filled circles and filled squares represent the results obtained with medium and IL-18, respectively. Open circles and open squares represent the class-matched control (IgG1) in the presence and absence of IL-18. *, P < 0.05 compared with the value for medium; **, P < 0.01 compared with the value for medium; #, P < 0.05 compared with the value for IL-18; ##, P < 0.01 compared with the value for IL-18. (B) Monocytes at 106 cells/ml were incubated with between 0 and 10–4 M indomethacin, NS398, and H-89 in the presence and absence of IL-18 (100 ng/ml) or CIP (100 µg/ml) for 24 h. Open squares, filled circles, and filled squares represent the results obtained with indomethacin, H-89, and NS398, respectively. **, P < 0.01 compared with the value for CIP; ##, P < 0.01 compared with the value for IL-18 and CIP. The results are the means ± SEM for five donors. When an error bar was within a symbol, the bar was omitted.

The effect of indomethacin, NS398, and H-89 on CIP-inhibited ICAM-1, B7.1, B7.2, and CD40 expression on monocytes. The effects of indomethacin, NS398, and H-89, a PKA inhibitor, between 0 and 10^–4 M on 100 µg/ml CIP-inhibited ICAM-1, B7.1, B7.2, and CD40 expression on monocytes in the presence and absence of 100 ng/ml IL-18 were determined by flow cytometry after 24 h of incubation (Fig. 4B and C). NS398 and indomethacin abolished the inhibitory effect of CIP on the expression of ICAM-1, B7.1, B7.2, and CD40 in the presence and absence of IL-18. In the presence of IL-18, H-89 blocked the CIP-initiated expression of ICAM-1, B7.2, and CD40 but had no effect on the expression of B7.1. The rates of ICAM-1 expression recovered by indomethacin, NS398, and H-89 at 10^–4 M were 68, 65, and 60%, respectively. In absence of IL-18, H-89 also had no effect on the CIP-initiated expression of ICAM-1, B7.1, B7.2, and CD40. However, these inhibitors had no effect in the absence of CIP (data not shown).

The effect of CIP on cytokine responses in PBMC. The effect of 0 to 100 µg/ml CIP on the production of IL-12, IFN-, TNF-, and IL-10 in PBMC incubated in medium in the presence and absence of IL-18 was determined by ELISA after 24 h (Fig. 5A). In IL-18-treated PBMC, CIP prevented the production of IL-12, IFN-, and TNF- but induced IL-10 production. The 50% inhibitory concentrations for the inhibitory effect of CIP on the production of IL-12, IFN-, and TNF- in the presence of IL-18 were estimated as 3, 3, and 2 µg/ml, respectively. In the absence of IL-18, CIP had no effect on cytokine production in the PBMC medium.

View larger version (26K): [in this window] [in a new window]

FIG. 5. The effect of CIP on cytokine response of PBMC. (A) PBMC at 106 cells/ml were treated with between 0 and 100 µg/ml CIP in the presence and absence of 100 ng/ml IL-18 for 24 h. After the treatment, IL-12, TNF-, IFN-, and IL-10 production was determined by ELISA. Filled circles and filled squares represent the results obtained with medium and IL-18, respectively. ##, P < 0.01 compared with the value for IL-18. (B) PBMC (106 cells/ml) were incubated with between 0 and 0.1 mM indomethacin, NS398, and H-89 in the presence and absence of 100 ng/ml IL-18 or 100 µg/ml CIP for 24 h. Open squares, filled circles, and filled squares represent the results obtained with indomethacin, H-89, and NS398, respectively. ##, P < 0.01 compared with the value for IL-18 and CIP. The results are the means ± SEM for five donors. When an error bar was within a symbol, the bar was omitted.

The effect of indomethacin, NS398, and H-89 on CIP-inhibited cytokine responses in PBMC. The effects of indomethacin, NS398, and H-89 (ranging between 0 and 10^–4 M) on the CIP-inhibited production of IL-12, IFN-, TNF-, and IL-10 in PBMC treated with 100 ng/ml IL-18 were determined by ELISA after 24 h of incubation (Fig. 5B). NS398, indomethacin, and H-89 blocked CIP-initiated production of TNF-, IL-12, IFN-, and IL-10. The rates of TNF- production recovered by indomethacin, NS398, and H-89 at 10^–4 M were 72, 63, and 61%, respectively. These inhibitors had no effect in the absence of CIP (data not shown).

Top Abstract Introduction Materials and Methods Results Discussion References

 
The present study examined for the first time the effects of CIP on the immune response of IL-18-treated monocytes. CIP induced the expression of COX-2 protein in monocytes treated with IL-18 or not treated (Fig. 1). In the absence and presence of IL-18, an unexpectedly large concentration 30 nM PGE₂ was detected in the medium of 100 µg/ml CIP-treated monocytes (Fig. 2A). CIP-initiated endogenous PGE₂ production was inhibited by the nonselective and selective COX-2 inhibitors indomethacin and NS398 (Fig. 2B), respectively, indicating that the increase in endogenous PGE₂ production might have depended on the enhancement of COX-2 expression. CIP as well as exogenous PGE₂ induced the elevation of intercellular cAMP in monocytes irrespective of the presence of IL-18 (Fig. 3). Also, CIP-enhanced cAMP expression was abolished by NS398. These results suggest that endogenously produced PGE₂ and the elevation of cAMP are associated with the CIP-induced enhancement of COX-2 expression.

Recently, we found that PGE₂ prevented IL-18-enhanced ICAM-1, B7.2, and CD40 expression through stimulation of the EP₂/EP₄ receptor (20). As shown in Fig. 4A, CIP suppressed IL-18-enhanced ICAM-1, B7.2, and CD40 expression on monocytes. Whereas the inhibitory effect of 100 µg/ml CIP on the expression of ICAM-1 was 50% (Fig. 4A), that of 30 nM exogenous PGE₂ was 35% (20). The inhibitors of COX-2 and PKA partially blocked the effect of CIP on IL-18-initiated adhesion molecule expression (Fig. 4B). Therefore, there might exist endogenous PGE₂-dependent and -independent pathways associated with the effects of CIP activity on adhesion molecule expression in the presence of IL-18. On the other hand, whereas PGE₂ had no effect on the adhesion molecule expression in the absence of IL-18 (20), CIP inhibited the expression of ICAM-1, B7.1, B7.2, and CD40 (Fig. 4A). The COX-2 inhibitors, but not the PKA inhibitor, abolished the adhesion molecule expression-suppressing effect of CIP in the absence of IL-18 (Fig. 4B), suggesting that the endogenous PGE₂ might not be involved in the effect of CIP in the absence of IL-18.

Previously, we reported that the inhibition of ICAM-1, B7.2, and CD40 expression on monocytes contributed to the suppression of IL-18-initiated cytokine production in PBMC (20, 21). PGE₂ inhibited the production of IL-12, IFN-, and TNF- but induced the production of IL-10 in PBMC treated with IL-18 (20). We found here that CIP mimicked the effect of PGE₂ on IL-18-initiated cytokine production (Fig. 5A). The inhibitors of COX-2 and PKA also blocked the effect of CIP on IL-18-initiated cytokine production (Fig. 5B). However, the rates of cytokine production as well as those of adhesion molecule expression recovered by indomethacin, NS398, and H-89 (10^–4 M) were similar and reached only between 60 and 70%. Therefore, the suppressive effect of CIP on IL-18-initiated cytokine production might depend on the inhibition of ICAM-1, B7.2, and CD40 expression.

IL-18 plays a role in inflammatory conditions, such as graft-versus-host disease (15) and Crohn's disease (14), and antimicrobial chemotherapy targeted against intestinal anaerobic bacteria significantly reduces the severity of the acute stage of these diseases (4, 13). CIP significantly ameliorates the severity of graft-versus-host disease and Crohn's disease by reducing the number of intestinal bacteria, some of which induce the lipopolysaccharide-initiated production of TNF- (1, 4, 19). In a randomized crossover study, the mean maximum concentration of CIP in the serum of normal human volunteers who received a single oral dose of 500 mg for up to 24 h was 2.46 µg/ml (7), which is within the range of the concentration noted in the present study. Therefore, the effects of CIP on immune responses may indicate new therapeutic potential for IL-18-induced diseases.

TOPO II-targeting drugs are apoptosis-inducing drugs, and both isoforms of TOPO II, alpha and beta, are inhibited by the chemotherapeutic agent etoposide (22). We found that etoposide had no effect on COX expression, adhesion molecule expression, and cytokine production in the absence and presence of IL-18 (data not shown). Cell viabilities of monocytes and lymphocytes in the presence of CIP and/or IL-18 were almost the same and were estimated to be 90% after 24 h of incubation. Therefore, the effect of CIP might be independent of the inhibition of TOPO II, and the regulation of cytokine production and adhesion molecule expression was not due to a reduction in cell viability. It is still unclear what the primary target or binding site of CIP in monocytes is for regulating immune responses. In conclusion, we found a regulation profile exists for the antimicrobial agent CIP on monocyte responses, as seen through increased PGE₂ production.

 
We thank Bayer Yakuhin, Ltd (Osaka, Japan) for generously donating CIP and for their financial support. This study was supported in part by a grant for the Promotion of Research from Okayama University (no. 21 to M.N.), a grant from the Okayama Medical Foundation (to H.K.T.), and a Grant-in-Aid for Scientific Research (C) (15590467 to H.K.T. and 15590228 to M.N.).

We also thank Yumiko Shiotani for her excellent technical assistance.

 
* Corresponding author. Mailing address: Department of Pharmacology, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. Phone and fax: 81-86-235-7140. E-mail: mbori{at}md.okayama-u.ac.jp.

Top Abstract Introduction Materials and Methods Results Discussion References

 

1
1. Bamias, G., M. Marini, C. A. Moskaluk, M. Odashima, W. G. Ross, J. Rivera-Nieves, and F. Cominelli. 2002. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J. Immunol. 169:5308-5314.[Abstract/Free Full Text]
2
2. Barbulescu, K., C. Becker, J. F. Schlaak, E. Schmitt, K.-H. Meyer zum Buschenfelde, and M. F. Neurath. 1998. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN- promoter in primary CD4+ T lymphocytes. J. Immunol. 160:3642-3647.[Abstract/Free Full Text]
3
3. Bastien, L., N. Sawyer, R. Grygorczyk, K. M. Metters, and M. Adam. 1994. Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. J. Biol. Chem. 269:11873-11877.[Abstract/Free Full Text]
4
4. Beelen, D. W., A. Elmaagacli, K. D. Muller, H. Hirche, and U. W. Schaefer. 1999. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 93:3267-3275.[Abstract/Free Full Text]
5
5. Brighty, K. E., and T. D. Gootz. 2000. Chemistry and mechanism of action of the quinolone antibacterials, p. 34-82. In V. T. Andriole (ed.), The quinolones, 3rd ed. Academic, San Diego, Calif.
6
6. Coleman, R. A., W. L. Smith, and S. Narumiya. 1994. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:205-229.[Medline]
7
7. Errington, F., E. Willmore, C. Leontiou, M. J. Tilby, and C. A. Austin. 2004. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity. Cancer Chemother. Pharmacol. 53:155-162.[CrossRef][Medline]
8
8. Gu, Y., K. Kuida, H. Tsutsui, G. Ku, K. Hsiao, M. A. Fleming, N. Hayashi, K. Higashino, H. Okamura, K. Nakanishi, M. Kurimoto, T. Tanimoto, R. A. Flavell, V. Sato, M. W. Harding, D. J. Livingston, and M. S. Su. 1997. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 275:206-209.[Abstract/Free Full Text]
9
9. Hempel, S. L., M. M. Monick, and G. W. Hunninghake. 1994. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J. Clin. Investig. 93:391-396.
10
10. Kohno, K., J. Kataoka, T. Ohtsuki, Y. Suemoto, I. Okamoto, M. Usui, M. Ikeda, and M. Kurimoto. 1997. IFN--inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J. Immunol. 158:1541-1550.[Abstract]
11
11. Nataraj, C., D. W. Thomas, S. L. Tilley, M. T. Nguyen, R. Mannon, B. H. Koller, and T. M. Coffman. 2001. Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse. J. Clin. Investig. 108:1229-1235.[CrossRef][Medline]
12
12. Okamura, H., H. Tsutsi, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, K. Akita, M. Namba, F. Tnabe, K. Konishi, S. Fukuda, and M. Kurimoto. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378:88-91.[CrossRef][Medline]
13
13. Peppercorn, M. A. 1993. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J. Clin. Gastroenterol. 17:235-237.[Medline]
14
14. Pizarro, T. T., M. H. Michie, M. Bentz, J. Woraratanadharm, M. F. Smith, Jr., E. Foley, C. A. Moskaluk, S. J. Bickston, and F. Cominelli. 1999. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J. Immunol. 162:6829-6835.[Abstract/Free Full Text]
15
15. Reddy, P., T. Teshima, M. Kukuruga, R. Ordemann, C. Liu, K. Lowler, and J. L Ferrara. 2001. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 194:1433-1440.[Abstract/Free Full Text]
16
16. Riesbeck, K. 2002. Immunomodulating activity of quinolones: review. J. Chemother. 14:3-12.[Medline]
17
17. Riesbeck, K., and A. Forsgren. 1995. CP-115,953 stimulates cytokine production by lymphocytes. Antimicrob. Agents Chemother. 39:476-483.[Abstract/Free Full Text]
18
18. Riesbeck, K., and A. Forsgren. 1990. Selective enhancement of synthesis of interleukin-2 in lymphocytes in the presence of ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 9:409-413.[CrossRef][Medline]
19
19. Riesbeck, K., and A. Forsgren. 1994. Increased interleukin 2 transcription in murine lymphocytes by ciprofloxacin. J. Immunopharmacol. 27:155-164.
20
20. Takahashi, H. K., H. Iwagaki, T. Yoshino, S. Mori, T. Morichika, H. Itoh, M. Yokoyama, S. Kubo, E. Kondo, T. Akagi, N. Tanaka, and M. Nishibori. 2002. Prostaglandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells. J. Immunol. 168:4446-4454.[Abstract/Free Full Text]
21
21. Takahashi, H. K., H. Iwagaki, R. Tamura, D. Xue, M. Sano, S. Mori, T. Yoshino, N. Tanaka, and M. Nishibori. 2003. Unique regulation profile of prostaglandin E1 on adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J. Pharmacol. Exp. Ther. 307:1188-1195.[Abstract/Free Full Text]
22
22. Wagenlehner, F. M., S. Wydra, H. Onda, M. Kinzig-Schippers, F. Sorgel, and K. G. Naber. 2003. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob. Agents Chemother. 47:3789-3794.[Abstract/Free Full Text]

---

Antimicrobial Agents and Chemotherapy, August 2005, p. 3228-3233, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3228-3233.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Takahashi, H. K., Iwagaki, H., Hamano, R., Yoshino, T., Tanaka, N., Nishibori, M. (2006). Effect of nicotine on IL-18-initiated immune response in human monocytes. J. Leukoc. Biol. 80: 1388-1394 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takahashi, H. K. Articles by Nishibori, M. Search for Related Content PubMed PubMed Citation Articles by Takahashi, H. K. Articles by Nishibori, M.